Chronic Kidney Disease Clinical Trial
Official title:
Endothelial Microparticles: A Novel Marker of Vascular Dysfunction
Verified date | February 2018 |
Source | University of Colorado, Denver |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
The primary hypothesis of this proposal is that chronic kidney disease (CKD) and treatment with calcineurin inhibitors (CNIs) are each associated with the release of endothelial microparticles into the plasma.
Status | Completed |
Enrollment | 90 |
Est. completion date | March 2016 |
Est. primary completion date | March 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility |
Inclusion Criteria: For Healthy controls: - BMI less than 40 kg/m^2 - Able to give informed consent For Stage III or IV CKD patients: - BMI less than 40 kg/m^2 - Able to give informed consent - An estimated Glomerular-Filtration Rate (GFR) of 20-60 mL/min/1.73m^2 For Post-kidney transplant and stage III or IV CKD patients: - BMI less than 40 kg/m^2 - Able to give informed consent - An estimated Glomerular-Filtration Rate (GFR) of 20-60 mL/min/1.73m^2 Exclusion Criteria: For Healthy controls: -Women pregnant or breastfeeding For Stage III or IV CKD patients: - Women pregnant or breastfeeding - Adults with a life expectancy of less than one year - A history of significant liver disease or congestive heart failure - Hospitalization within the last three months - Active infection on antibiotic therapy - Uncontrolled hypertension (>140/90) - Immunosuppressive therapy within the last year For Post-transplant stage III or IV CKD patients: - Women pregnant or breastfeeding - Adults with a life expectancy of less than one year - A history of significant liver disease or congestive heart failure - Hospitalization within the last three months - Active infection on antibiotic therapy - Uncontrolled hypertension (>140/90) |
Country | Name | City | State |
---|---|---|---|
United States | University of Colorado Anschutz Medical Campus; CTRC | Aurora | Colorado |
United States | University of Colorado School of Medicine | Aurora | Colorado |
Lead Sponsor | Collaborator |
---|---|
University of Colorado, Denver |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Vascular Function | This will be measured with flow-mediated dilation and evaluate percent change from baseline over minutes. | percent change from baseline over 2 minutes | |
Secondary | Characterization of Microparticle source from blood analysis | A single blood draw to distinguish micro particle source characterization based upon protein, lipid and cholesterol composition. | Single time point |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |